UnitedHealth Group (UNH) Financial Research Report

Disclaimer#

This content reflects the views of the author(s) as of the date indicated and is for educational and informational purposes only. It does not constitute investment advice. Please do your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results.

Latest Quarter Earnings#

The latest available quarter is Q3 2025. UnitedHealth Group reported consolidated revenues of $113.2 billion, representing a 12% year-over-year increase. Earnings from operations were $4.3 billion and GAAP earnings per share were $2.59 (adjusted EPS $2.92). The medical care ratio was 89.9% and the operating cost ratio 13.5%. UnitedHealthcare generated $87.1 billion of revenue and served 50.1 million consumers, while Optum produced $69.2 billion of revenue. The company's debt-to-capital ratio stood at 44.1%【173314924561626†L189-L203】.

Background Research#

UnitedHealth Group operates through two primary segments: UnitedHealthcare, which provides health insurance coverage for employers, individuals, seniors (Medicare Advantage), Medicaid beneficiaries and supplemental plans; and Optum, which delivers health services through Optum Health, Optum Insight and Optum Rx, offering care delivery, analytics and pharmacy benefit management. Risk‑based premium revenue accounted for roughly 74% of 2024 revenue, with the remainder coming from services and pharmacy benefit management fees【219362315749609†L3215-L3339】.

The company's domestic medical membership numbered about 49.3 million people in 2024, comprising 29.7 million commercial members, 7.8 million Medicare Advantage members, 7.4 million Medicaid members and 4.3 million Medicare Supplement members. Total membership including global operations was 50.7 million【219362315749609†L3215-L3339】. Optum Health served approximately 100 million individuals and Optum Rx filled 1.62 billion prescriptions【219362315749609†L3366-L3395】.

UnitedHealth Group's competitive advantages include its scale, an integrated insurance-care-pharmacy platform, strong brand recognition, proprietary data analytics and an extensive provider network. Short‑term headwinds include elevated medical costs (MCR ~85.5%), a post‑pandemic rebound in utilization, Medicaid eligibility redeterminations and cybersecurity incidents. Long‑term risks relate to changes in government reimbursement, pricing pressure, healthcare reform and competition. The company's cost structure is dominated by medical claims (about 86% of premium revenue), while operating costs such as labour, marketing, technology and administration represent roughly 13% of revenue【219362315749609†L2890-L2934】.

Financial Research#

UnitedHealth's revenue expanded from $157 billion in 2015 to $400.3 billion in 2024 (CAGR ≈ 11.6%). Net income rose from $5.8 billion to $14.4 billion, although earnings declined in 2024 due to higher medical costs【652437760855284†L45-L60】【24035283728800†L45-L55】. The gross margin has remained around 22%, the operating margin around 8% and the net margin roughly 4%【847109371080807†L44-L56】【984635477612388†L44-L56】. Free cash flow grew from $8.2 billion to $20.7 billion, maintaining FCF margins of 4-6% and positive every year【43311334469421†L43-L53】. Return on equity averaged about 15%, return on invested capital around 13% and return on assets about 6%. Debt‑to‑equity increased from 0.75 in 2015 to 2.03 in 2024, partly due to share repurchases and acquisitions; debt‑to‑assets is approximately 0.67【207341877580065†L38-L50】. The company held $29 billion in cash and cash equivalents and $72 billion of long‑term debt【773606662045407†L41-L54】.

The stock price climbed from roughly $100 in 2015 to about $497 at the end of 2024. The trailing P/E ratio as of late 2025 is around 14.4, below the 10‑year average of about 22【273950816045526†L141-L154】. The P/B ratio is roughly 2.9 compared with a historical average near 4.4【526149587376100†L145-L156】. Consistent dividends (yield ~1.5%) and share repurchases have reduced shares outstanding from 967 million in 2015 to 929 million in 2024【415810637407076†L42-L53】. In 2024 the company repurchased $9 billion of shares and the board authorized a program to repurchase up to 35 million shares without expiration【219362315749609†L2373-L2383】.

Ten‑Year Financial Metrics Table#

Selected Metric Trends#

The following charts illustrate the 2015-2024 trends for selected metrics. The red dashed line indicates the 10‑year average, and the red/ orange dots mark the maximum and minimum values.

Deep Value Investing Assessment#

Using deep value criteria (P/E ≤ 15, PEG < 1, P/B ≤ 1.5, FCF/Revenue > 5%, Return on retained earnings ≥ 12%, positive & rising EPS, book value growth ≥ 10%, OE/Market Cap ≥ 10%, debt/equity < 0.5, interest coverage ≥ 3×, current ratio > 1.5, margins and returns above thresholds):

• Valuation: P/E (≈ 14.4) meets the ≤ 15 requirement; PEG (≈ 0.87 using 10‑yr EPS CAGR ≈ 13%) passes; P/B (≈ 2.9) exceeds the 1.5 threshold; margin‑of‑safety (current price vs intrinsic value) discussed below.

• Cash generation & allocation: FCF was positive every year with FCF/Revenue mostly 4-6% (exceeds 5%). Return on retained earnings averaged around 14%, passing the 12% threshold.

• Growth & predictability: EPS trended upward for most years but dipped in 2024. Book value per share grew at a 10‑yr CAGR of ~13%, but 2024 growth was modest. Owner's earnings (approximated by FCF) were positive and averaged ~5% of market cap, below the 10% threshold.

• Balance‑sheet safety: Debt‑to‑equity rose above 2, failing the < 0.5 standard; interest coverage remained strong (operating income vs interest) but current ratio is around 0.8, below the 1.5 benchmark.

• Profitability & efficiency: Gross margin (~22%), operating margin (~8%), ROE (~15%) and ROIC (~13%) meet or exceed the suggested thresholds; net margin (~4%) falls short of the 20% deep value benchmark. Depreciation/Gross profit ratio is well below 10%.

Overall, UnitedHealth Group satisfies several deep value criteria - notably low P/E, robust cash generation and high returns on equity - but fails others such as P/B, leverage and net margin. Investors should weigh these factors alongside qualitative assessments of competitive positioning and risk.

Discounted Cash Flow (DCF) Analysis#

The DCF model uses 2024 free cash flow of $20.705 billion as a starting point and an 8% discount rate. Terminal growth is assumed at 2%. Four scenarios were analysed:

• No‑growth (FCF growth = 0%): intrinsic value ≈ $325 per share; buy price with 30% margin of safety ≈ $227.

• Conservative (growth at the lowest 10‑yr FCF growth of -19.4%): intrinsic value ≈ $210 per share; buy price ≈ $147.

• Nominal (growth at average 10‑yr FCF growth ~12.2%): intrinsic value ≈ $829 per share; buy price ≈ $581.

• Optimistic (growth at the highest 10‑yr FCF growth of 43%): intrinsic value ≈ $1,373 per share; buy price ≈ $961.

Actual market price (~$497 at year‑end 2024) is below the nominal DCF value but above the no‑growth and conservative values. The large spread between scenarios underscores the sensitivity of valuations to growth assumptions. Investors should adopt conservative inputs and consider uncertainties in future medical cost trends and regulation.

Conclusion#

UnitedHealth Group is the largest private‑sector health insurer in the United States with a diversified platform spanning insurance, care delivery, analytics and pharmacy services. Over the past decade the company has delivered strong revenue and earnings growth, healthy returns on equity and robust free cash flow. However, margins remain thin due to the nature of the health insurance business, and leverage has increased because of acquisitions and share repurchases. Regulatory changes, medical cost inflation and technological disruptions present ongoing risks. Investors interested in UnitedHealth should evaluate whether the current valuation adequately compensates for these risks and whether the company's scale and integrated model provide a durable competitive advantage.

Note: This report is for educational purposes only and should not be considered investment advice. All financial data are based on publicly available sources and may be subject to revisions or differing interpretations.